Food and Drug Administration (FDA)
NEWS
The StrataGraft is designed to help heal patients who have received thermal burns that would ultimately require a skin graft. Here’s everything about it.
Eli Lilly and Company announced Tuesday the launch of a head-to-head study to compare once-monthly injectable Emgality® (galcanezumab-gnlm) with Nurtec® ODT (rimegepant) for the prevention of migraine.
A recent study conducted by Public Health England found that the available vaccines were “highly effective” at preventing hospitalization after two doses.
The study drug is a once-daily, two-week therapy developed by Sage Therapeutics and Biogen for major depressive disorder (MDD) and postpartum depression (PPD).
The company noted it would continue to assess the STAR study’s complete data set before confirming its future plans for clinical development of timrepigene emparvovec.
The failure marks a setback in the hunt for means other than vaccines to provide protection against the novel coronavirus and its variants.
The new division would benefit from Hahn’s experience and help steer the company’s Preemptive Medicine and Health Security initiative.
Avenue Therpeutics is facing the heat of rejection from FDA once again for its IV non-opioid painkiller tramadol. Here are the reasons behind the rejections
The FDA accepted its pre-Investigational New Drug request for a cell therapy treatment that could be a key factor in controlling HIV.
JOBS
IN THE PRESS